Arginine Malaria Trial: Study of Adjunctive Arginine in Falciparum Malaria

Status Completed

Clinical Trial Summary

Acute falciparum malaria is associated with low plasma arginine and impaired nitric oxide (NO) production. Both are associated with poor outcome. This study will examine the safety and effect of escalating doses of arginine in falciparum malaria. It will determine whether arginine can increase NO production and have an effect on NO-dependent physiological measurements. The hypothesis is that arginine: will be safe in falciparum malaria; will return plasma arginine concentration to normal/supranormal levels; will increase systemic and exhaled NO; reduces oxidant stress; and improves a number of NO-dependent physiological measures of relevance to malaria.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00147368
Study type	Interventional
Source	Menzies School of Health Research
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	February 2005
Completion date	December 2007

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02329301` - Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia	N/A
Recruiting	`NCT01944189` - Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics and Population Pharmacokinetics	Phase 4
Completed	`NCT01325974` - Time to Become Negative of Three Rapid Diagnostic Tests for Malaria	N/A
Terminated	`NCT01442168` - Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria	Phase 1/Phase 2
Completed	`NCT00375128` - Sporozoite Challenge of Polyprotein Vaccinees	Phase 1/Phase 2
Terminated	`NCT00374205` - Randomized Trial on Effectiveness of ACTs in Ghana	Phase 4
Completed	`NCT04609098` - Single Low Dose Tafenoquine to Reduce P. Falciparum Transmission in Mali (NECTAR2)	Phase 2
Completed	`NCT02851108` - Methylene Blue Against Falciparum Malaria in Burkina Faso	Phase 2
Completed	`NCT02434952` - Safety and Tolerability of Low Dose Primaquine	Phase 4
Terminated	`NCT02281344` - MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants	Phase 1
Completed	`NCT01213966` - Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection	Phase 2
Completed	`NCT00479206` - Artemisinin Resistance in Cambodia	N/A
Completed	`NCT00126906` - Prevention of Malaria During Pregnancy Using Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: Malawi	N/A
Completed	`NCT01019408` - Extended-dose Chloroquine (ECQ) for Resistant Falciparum Malaria Among Afghan Refugees in Pakistan	Phase 4
Completed	`NCT00529867` - Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria	Phase 4
Completed	`NCT00137553` - The Efficacy of Re-treatment With Sulfadoxine-pyrimethamine in Children	Phase 4
Completed	`NCT02637128` - In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria	Phase 4
Completed	`NCT01222962` - Food Interaction Study on the Pharmacokinetics of Eurartesim™ (DHA and PQP)in Healthy Male Adult Volunteers	Phase 1
Unknown status	`NCT00152204` - The Community Effectiveness of IPTi in Southern Tanzania	Phase 3
Terminated	`NCT00084240` - Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia	Phase 2/Phase 3